{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:58:51Z","timestamp":1780635531635,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007606","name":"Aarhus University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction and objective<\/jats:title>\n            <jats:p>Intradetrusor Botulinum Neurotoxin Type A (BoNT-A) is an increasingly applied treatment modality for overactive bladder (OAB) in children with refractory urinary incontinence. Despite that, evidence is sparse, and the potential not fully understood. The aim of this study was to evaluate the effectiveness and safety of intradetrusor injection in children with refractory functional OAB and urinary incontinence. Furthermore, we aimed to identify predictors of efficacy and side effects to BoNT-A treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>We conducted a cohort study of children with OAB and urinary incontinence who received intradetrusor injection of BoNT-A in the period 01.01.2016 to 31.12.2020 at our centre. All patients were refractory to standard urotherapy, anticholinergics, mirabegron and the combination of these treatments. Patients with neurogenic bladder were excluded.<\/jats:p>\n            <jats:p>Primary endpoint was the reduction on the frequency of urinary incontinence episodes from baseline. Secondary endpoints included urodynamic parameters and uroflowmetry characteristics as well as side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty-three children (mean age at first treatment 10.7\u2009\u00b1\u20091.8, 30 males) were included.<\/jats:p>\n            <jats:p>After first treatment, a reduction of\u2009\u2265\u200950% in incontinence episodes was seen in 58% of patients with daytime urinary incontinence (DUI) and 47% of patients with nocturnal enuresis (NE). Adverse events, mainly urinary tract infections (UTI), were reported by 16% of patients after first treatment. Our analysis identified normal cystometric compliance as a significant predictor of treatment effect We estimated the mean duration of effect to be approximately 7\u00a0months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Intradetrusor BoNT-A injection appears to be a safe and effective option in treating refractory urinary incontinent children with overactive bladder. We identified cystometric compliance as a predictor of response. Most children necessitate repeated treatments. Further prospective and controlled studies are necessary in order to fully identify predictors and potential of treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11255-024-04217-z","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T17:02:17Z","timestamp":1727370137000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Botulinum Neurotoxin Type A in paediatric non-neurogenic therapy resistant overactive bladder: a cohort study"],"prefix":"10.1007","volume":"57","author":[{"given":"Nicklas B.","family":"Hougaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Breinbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kamperis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Skott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"4","key":"4217_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/nau.22751","volume":"35","author":"PF Austin","year":"2016","unstructured":"Austin PF, Bauer SB, Bower W et al (2016) The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children\u2019s Continence Society. Neurourol Urodyn 35(4):471\u2013481. https:\/\/doi.org\/10.1002\/nau.22751","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"4217_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","volume":"75","author":"S Bartoli","year":"2010","unstructured":"Bartoli S, Aguzzi G, Tarricone R (2010) Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology 75(3):491\u2013500. https:\/\/doi.org\/10.1016\/j.urology.2009.07.1325","journal-title":"Urology"},{"issue":"1","key":"4217_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/nau.22911","volume":"36","author":"SJ Chang","year":"2017","unstructured":"Chang SJ, Van Laecke E, Bauer SB et al (2017) Treatment of daytime urinary incontinence: a standardization document from the International Children\u2019s Continence Society. Neurourol Urodyn 36(1):43\u201350. https:\/\/doi.org\/10.1002\/nau.22911","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"4217_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/j.1464-410X.2010.09317.x","volume":"105","author":"Y-C Chuang","year":"2010","unstructured":"Chuang Y-C, Kuo H-C, Chancellor MB (2010) Botulinum toxin for the lower urinary tract. BJU Int 105(8):1046\u20131058. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09317.x","journal-title":"BJU Int"},{"issue":"9","key":"4217_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nrurol.2016.152","volume":"13","author":"I Franco","year":"2016","unstructured":"Franco I (2016) Overactive bladder in children. Nat Rev Urol 13(9):520\u2013532. https:\/\/doi.org\/10.1038\/nrurol.2016.152","journal-title":"Nat Rev Urol"},{"issue":"1","key":"4217_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/s0022-5347(06)00301-6","volume":"176","author":"P Hoebeke","year":"2006","unstructured":"Hoebeke P, De Caestecker K, Vande Walle J et al (2006) The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 176(1):328\u2013330. https:\/\/doi.org\/10.1016\/s0022-5347(06)00301-6","journal-title":"J Urol"},{"issue":"2","key":"4217_CR7","doi-asserted-by":"publisher","first-page":"181.e1","DOI":"10.1016\/j.jpurol.2019.12.013","volume":"16","author":"A Ringoir","year":"2020","unstructured":"Ringoir A, Dhondt B, De Bleser E et al (2020) Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study. J Pediatr Urol 16(2):181.e1-181.e8. https:\/\/doi.org\/10.1016\/j.jpurol.2019.12.013","journal-title":"J Pediatr Urol"},{"issue":"3","key":"4217_CR8","doi-asserted-by":"publisher","first-page":"351.e1","DOI":"10.1016\/j.jpurol.2022.02.007","volume":"18","author":"AP Lambregts","year":"2022","unstructured":"Lambregts AP, Nieuwhof-Leppink AJ, Klijn AJ, Schroeder RPJ (2022) Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder. J Pediatr Urol 18(3):351.e1-351.e8. https:\/\/doi.org\/10.1016\/j.jpurol.2022.02.007","journal-title":"J Pediatr Urol"},{"issue":"1","key":"4217_CR9","doi-asserted-by":"publisher","first-page":"32.e1","DOI":"10.1016\/j.jpurol.2018.08.007","volume":"15","author":"J Ingham","year":"2019","unstructured":"Ingham J, Angotti R, Lewis M, Goyal A (2019) Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes. J Pediatr Urol 15(1):32.e1-32.e5. https:\/\/doi.org\/10.1016\/j.jpurol.2018.08.007","journal-title":"J Pediatr Urol"},{"issue":"3","key":"4217_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-0029-1246193","volume":"20","author":"A Marte","year":"2010","unstructured":"Marte A, Borrelli M, Sabatino MD et al (2010) Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg 20(3):153\u2013157. https:\/\/doi.org\/10.1055\/s-0029-1246193","journal-title":"Eur J Pediatr Surg"},{"issue":"8","key":"4217_CR11","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/nau.23729","volume":"37","author":"JG Wen","year":"2018","unstructured":"Wen JG, Djurhuus JC, Rosier P, Bauer SB (2018) ICS educational module: Cystometry in children. Neurourol Urodyn 37(8):2306\u20132310. https:\/\/doi.org\/10.1002\/nau.23729","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"4217_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jpurol.2019.12.020","volume":"16","author":"T Nev\u00e9us","year":"2020","unstructured":"Nev\u00e9us T, Fonseca E, Franco I et al (2020) Management and treatment of nocturnal enuresis-an updated standardization document from the International Children\u2019s Continence Society. J Pediatr Urol 16(1):10\u201319. https:\/\/doi.org\/10.1016\/j.jpurol.2019.12.020","journal-title":"J Pediatr Urol"},{"key":"4217_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2023.10.034","author":"SAA Hoelscher","year":"2023","unstructured":"Hoelscher SAA, de Angst IB, Buijnsters ZA et al (2023) The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review. J Pediatr Urol. https:\/\/doi.org\/10.1016\/j.jpurol.2023.10.034","journal-title":"J Pediatr Urol"},{"key":"4217_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13070447","author":"SY Wu","year":"2021","unstructured":"Wu SY, Chang SJ, Yang SS, Hsu CK (2021) Botulinum toxin injection for medically refractory neurogenic bladder in children: a systematic review. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins13070447","journal-title":"Toxins (Basel)."}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04217-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04217-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04217-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T18:57:06Z","timestamp":1738004226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04217-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["4217"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04217-z","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}